Embecta restructures again, outlines tariff costs

The diabetes tech company announced a second restructuring after ending its insulin patch-pump program.

By Elise Reuter • May 13, 2025

Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.

By Elise Reuter • May 12, 2025

New Insulet CEO Ashley McEvoy sets priorities

The diabetes tech company raised its expectations for revenue and gross margins, despite the impact of tariffs.

By Elise Reuter • May 9, 2025

ADA’s Osagie Ebekozien on diabetes tech for Type 2, new CGM standards

Ebekozien, chief quality officer of the American Diabetes Association, said the nonprofit is seeing a shift with more devices authorized for Type 2 diabetes.

By Elise Reuter • May 9, 2025

Abbott integrates diabetes data into Epic’s electronic health records

Linking the systems will allow clinicians to view glucose data captured by Libre glucose sensors within Epic’s systems.

By Nick Paul Taylor • May 1, 2025

Senseonics, Sequel partner to use 1-year CGM in automated insulin dosing system

The partnership extends the compatibility of Sequel’s Twiist system to allow people with Type 1 diabetes to pair the device with Senseonics’ Eversense 365 CGM.

By Nick Paul Taylor • April 30, 2025

Ashley McEvoy named Insulet CEO

McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of Insulet for three years, resigned on Monday but will work as a consultant.

By Elise Reuter • April 28, 2025

Medtronic seeks FDA nod for insulin pump, furthering Abbott collab

Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by Abbott.

By Elise Reuter • April 24, 2025

Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps

The updated device allows users to pair the sensor with Medtronic’s insulin pumps, and is expected to grow the company’s diabetes business.

By Elise Reuter • April 21, 2025

Illumina, Tempus AI partner to drive genomic testing beyond cancer

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

By Nick Paul Taylor • April 18, 2025

Dexcom nets FDA clearance for 15-day CGM

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

By Elise Reuter • April 10, 2025

Tariffs send healthcare industry into ‘unchartered waters’

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain. Wall Street, meanwhile, said medtech businesses will face pressure, particularly diabetes tech firms.

By Susanna Vogel , Susan Kelly • April 4, 2025

Tandem eyes Medicare coverage expansion for Type 2

CMO Jordan Pinsker said Tandem hopes to expand Medicare coverage of its automated insulin delivery systems using new data shared at ATTD.

By Elise Reuter • March 31, 2025

Newly public Beta Bionics reports sales surge; Dexcom hires CCO

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.

By Nick Paul Taylor • March 28, 2025

Dexcom rejects claims of unauthorized device changes in FDA warning letter

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its glucose sensors.

By Elise Reuter • March 27, 2025

Dexcom’s FDA warning letter reveals unauthorized changes to sensors

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, according to the warning letter.

By Elise Reuter • March 26, 2025

Dexcom COO on 15-day glucose sensor, Type 2 coverage

Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and an FDA warning letter.

By Elise Reuter • March 25, 2025

Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

By Elise Reuter • March 20, 2025

Insulet Chief Technology Officer Mark Field leaves

Amit Guliani, group vice president of software engineering, was named acting chief technology officer, effective immediately.

By Elise Reuter • March 18, 2025

Dexcom receives warning letter based on FDA inspections of 2 plants

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek clearance for new products.

By Nick Paul Taylor • March 10, 2025

Illumina to lay off 96 San Diego employees

The latest job cuts at Illumina’s California headquarters are not part of a broad-based reduction, a company spokesperson said.

By Susan Kelly • Feb. 28, 2025

Tandem’s insulin pump tech wins FDA nod for Type 2 diabetes

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

By Elise Reuter • Feb. 27, 2025

Illumina placed on China’s unreliable entity list

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s genome sequencing market.

By Susan Kelly • Feb. 5, 2025

Beta Bionics raises $204M in IPO

The diabetes tech firm began trading this week and was valued at $966.2 million as of Thursday.

By Elise Reuter • Jan. 31, 2025

Neko Health raises $260M to expand body scan service, fund R&D

The company uses various medical devices to noninvasively check moles, the heart and more.

By Nick Paul Taylor • Jan. 28, 2025